AR086448A1 - Composicion farmaceutica que comprende drotaverina - Google Patents

Composicion farmaceutica que comprende drotaverina

Info

Publication number
AR086448A1
AR086448A1 ARP120101763A ARP120101763A AR086448A1 AR 086448 A1 AR086448 A1 AR 086448A1 AR P120101763 A ARP120101763 A AR P120101763A AR P120101763 A ARP120101763 A AR P120101763A AR 086448 A1 AR086448 A1 AR 086448A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
drotaverina
composition including
preparation
pharmaceutical
Prior art date
Application number
ARP120101763A
Other languages
English (en)
Inventor
Sudhakara Rao Badabhagni
Nilesh Jaiswal
Praveen Khullar
K U M Prasad
Original Assignee
Chinoin Private Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Private Co Ltd filed Critical Chinoin Private Co Ltd
Publication of AR086448A1 publication Critical patent/AR086448A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica de hidrocloruro de drotaverina en un sistema de disolvente adecuada como una composición líquida de relleno. Un proceso para la preparación de dicha composición farmacéutica y al uso de dicha composición para la preparación de un producto farmacéutico para tratar espasmos y dolores agudos.Reivindicación 1: Una composición farmacéutica para administración oral, que comprende: de 5 a 30% (p/p) de hidrocloruro de drotaverina; al menos 60% (p/p) de una mezcla líquida de al menos un tensioactivo no iónico hidrofílico y al menos un tensioactivo no iónico hidrofóbico. Reivindicación 4: La composición farmacéutica según la reivindicación 1, en la que el tensioactivo no iónico hidrofóbico es monocaprilato de propilen glicol. Reivindicación 7: La composición farmacéutica según la reivindicación 1, en la que el tensioactivo no iónico hidrofílico es el polisorbato 80.
ARP120101763A 2011-05-20 2012-05-18 Composicion farmaceutica que comprende drotaverina AR086448A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1728CH2011 2011-05-20
US201161499850P 2011-06-22 2011-06-22
EP11305922 2011-07-13

Publications (1)

Publication Number Publication Date
AR086448A1 true AR086448A1 (es) 2013-12-11

Family

ID=47216628

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101763A AR086448A1 (es) 2011-05-20 2012-05-18 Composicion farmaceutica que comprende drotaverina

Country Status (10)

Country Link
US (1) US20140080864A1 (es)
EP (1) EP2709599B1 (es)
AR (1) AR086448A1 (es)
BR (1) BR112013029621A2 (es)
EA (1) EA022944B1 (es)
HU (1) HUE038538T2 (es)
MX (1) MX354485B (es)
PL (1) PL2709599T3 (es)
UY (1) UY34081A (es)
WO (1) WO2012159964A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011196A (es) 2020-03-09 2022-09-19 Sushma Paul Berlia Formulaciones de liberacion controlada que comprenden drotaverina o una sal de la misma.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197207B (en) * 1985-12-04 1989-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical comprising 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydro-isoquinolinium-theophylline-7-acetate or its monohydrate as active ingredient
HUT60926A (en) * 1991-04-12 1992-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition suitable for reducing or preventing increased thrombocyte-aggregation capability
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
EA201391743A1 (ru) 2014-03-31
PL2709599T3 (pl) 2018-07-31
MX2013013574A (es) 2014-09-22
US20140080864A1 (en) 2014-03-20
WO2012159964A1 (en) 2012-11-29
EP2709599A1 (en) 2014-03-26
EP2709599B1 (en) 2017-12-20
HUE038538T2 (hu) 2018-10-29
BR112013029621A2 (pt) 2016-12-13
MX354485B (es) 2018-03-07
EA022944B1 (ru) 2016-03-31
UY34081A (es) 2013-01-03

Similar Documents

Publication Publication Date Title
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
ES2721325T3 (es) Método para producir de manera estéril partículas de lípido-ácido nucleico
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
PE20140255A1 (es) Tableta dispersable en forma oral
GT201200158A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
UY39192A (es) Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CL2013000715A1 (es) Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih.
CL2012000261A1 (es) Composición farmacéutica líquida de ácido 4- {[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico en una mezcla de disolventes con al menos 15% de propilenglicol, 15% de peg400 y menos de 50% de agua; y su uso para la preparación de un medicamento para el tratamiento de cáncer.
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
JP2014129360A5 (es)
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
CL2018003178A1 (es) Composición farmacéutica
AR082566A1 (es) Formulaciones liquidas de st-246 y metodos relacionados, proceso
CL2009000902A1 (es) Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
BR112014028069A2 (pt) composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
CL2013002650A1 (es) Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
CL2011002302A1 (es) Uso de una composicion que comprende un monocaprina y un diluyente farmaceuticamente aceptable para el tratamiento de una condicion micotica causada por trichophyton rubrum tal como tinea pedis, tinea crusis, dermatofitosis y onicomicosis.
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
AR093402A1 (es) Producto de comicronizacion que comprende acetato de ulipristal
BR112014000080A8 (pt) dispositivo de reconstituição

Legal Events

Date Code Title Description
FB Suspension of granting procedure